Stocks Health care IART
NASDAQ · Health careIntegra Lifesciences Holdings Corp (IART)
Integra Lifesciences Holdings Corp brought in $1.7B of revenue over the twelve months to September 30, 2026, up 0.8% from a year earlier. Net income was $13M, a net margin of 0.8%. In fiscal 2025 capital spending exceeded operating cash flow by $31.1M. At September 30, 2026 it held $252.3M in cash against $697.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 23, 2026.
Key facts about Integra Lifesciences Holdings Corp
- Net worth
- Integra Lifesciences Holdings Corp has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.6B (+1.5% year on year), with a net loss of $516.5M. Over the 12 months to September 30, 2026: revenue $1.7B, net income $13M.
- Cash flow
- In fiscal 2025 operations brought in $50.4M of cash; after $81.4M of capital spending, free cash flow was -$31.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 23, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Integra Lifesciences Holdings Corp's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Integra Lifesciences Holdings Corp does
Integra Lifesciences Holdings Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker IART.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.6B | -$516.5M | -$6.74 | -$31.1M |
| 2024 | $1.6B | -$6.9M | -$0.09 | $25M |
| 2023 | $1.5B | $67.7M | $0.84 | $73.1M |
| 2022 | $1.6B | $180.6M | $2.16 | $222.1M |
| 2021 | $1.5B | $169.1M | $1.98 | $264.4M |
| 2020 | $1.4B | $133.9M | $1.57 | $164.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IART ranks in Health care
Latest SEC filings
What Integra Lifesciences Holdings Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 23, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 2.3% to $411.2M versus the same quarter last year; diluted EPS $0.19 versus -$0.07.
- October 21, 2026
- October 19, 2026
- October 9, 2026
- October 2, 2026Quarterly results8-KIntegra LifeSciences announced preliminary third-quarter financial results and lowered its full-year 2026 outlook due to supply disruptions from flooding at its Cincinnati facility.
- September 8, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 0.8% to $418.8M versus the same quarter last year; diluted EPS $0.06 versus -$6.31.
- July 29, 2026
Insider trades
What the people running Integra Lifesciences Holdings Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Veillon-Berteloot ChantalEVP & CHRO | Shares withheld for tax | 1,455 | $24.2K |
| July 3, 2026 | Knight Lea DanielsEVP & Chief Financial Officer | Shares withheld for tax | 5,226 | $94.3K |
| July 1, 2026 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Shares withheld for tax | 937 | $16.8K |
| May 9, 2026 | Bradley KeithDirector | Shares withheld for tax | 882 | $12.3K |
| May 7, 2026 | Hill Barbara BDirector | Received as pay | 6,638 | - |
| May 7, 2026 | Hill Barbara BDirector | Received as pay | 17,700 | - |
| March 11, 2026 | Davis Robert T. Jr.EVP & President, TT | Shares withheld for tax | 8,487 | $81.6K |
| March 11, 2026 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Shares withheld for tax | 806 | $7.7K |
Who owns IART
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13G, passive with 1 related filers | 9.46% | July 9, 2025 |
| Paradigm Capital Management Inc13G, passive | 5.2% | May 15, 2026 |
| Vanguard Portfolio Management13G, passive | 5.02% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 212 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,684,103 | +364,934 |
| Rubric Capital Management LP | 7,753,934 | 0 |
| Invesco Ltd. | 3,749,367 | +263,764 |
| Vanguard Portfolio Management LLC | 3,743,093 | +56,456 |
| Morgan Stanley | 3,593,079 | +8,924 |
| Paradigm Capital Management Inc | 3,439,098 | -573,600 |
| Fuller & Thaler Asset Management, Inc. | 3,436,006 | -93,398 |
| State Street Corp | 2,946,862 | +60,306 |
| Vanguard Capital Management LLC | 2,946,173 | +55,349 |
| Neuberger Berman Group LLC | 2,364,777 | +249,522 |
| Dimensional Fund Advisors LP | 2,216,653 | -558,335 |
| Geode Capital Management, LLC | 1,791,635 | +134,650 |
| Goldman Sachs Group Inc | 1,473,719 | -403,031 |
| Wellington Management Group Llp | 1,461,104 | +160,814 |
| Millennium Management LLC | 1,439,747 | +816,894 |
| Charles Schwab Investment Management Inc | 1,401,476 | -210,669 |
| Bank of America Corp | 1,329,251 | -85,258 |
| Systematic Financial Management LP | 1,023,243 | -36,043 |
| Allianz Asset Management GmbH | 1,005,203 | +115,599 |
| Glenmede Trust Co NA | 948,142 | -36,544 |
Insiders
8 insiders reported holding 502,548 shares in total, about $7.2M at the last price.
| Holder | Shares |
|---|---|
| Hill Barbara BDirector | 151,191 |
| Bradley KeithDirector | 88,254 |
| Davis Robert T. Jr.EVP & President, TT | 66,387 |
| McBreen Michael J.EVP & President, CSS | 60,743 |
| Knight Lea DanielsEVP & Chief Financial Officer | 45,263 |
| Singh HarvinderEVP & PRESIDENT, INTERNATIONAL | 35,422 |
| Mosebrook JeffreySVP, Fin & Princ Acct Officer | 34,516 |
| Veillon-Berteloot ChantalEVP & CHRO | 20,772 |
Questions about IART
What does Integra Lifesciences Holdings Corp do?
Integra Lifesciences Holdings Corp is a company in the Health care sector, listed on NASDAQ as IART. Its shares trade on NASDAQ under the ticker IART.
What is Integra Lifesciences Holdings Corp's net worth?
Integra Lifesciences Holdings Corp has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Integra Lifesciences Holdings Corp profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $13M on revenue of $1.7B, a net margin of 0.8%.
How much revenue does Integra Lifesciences Holdings Corp make?
Over the twelve months to September 30, 2026 Integra Lifesciences Holdings Corp reported revenue of $1.7B. That is 0.8% more than a year earlier.
When did Integra Lifesciences Holdings Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 23, 2026. It covers the period to September 30, 2026.
When is Integra Lifesciences Holdings Corp's next earnings report?
Integra Lifesciences Holdings Corp's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IART with
Follow IART
Get an email when Integra Lifesciences Holdings Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Integra Lifesciences Holdings Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.